Integer (NYSE:ITGR) Given New $130.00 Price Target at Citigroup

Integer (NYSE:ITGR) had its price target raised by Citigroup from $124.00 to $130.00 in a research note published on Tuesday, Benzinga reports. Citigroup currently has a neutral rating on the medical equipment provider’s stock.

Several other research analysts also recently commented on ITGR. Benchmark restated a buy rating and issued a $130.00 target price on shares of Integer in a research note on Friday, August 2nd. Bank of America boosted their price objective on shares of Integer from $135.00 to $145.00 and gave the company a buy rating in a research note on Tuesday. Truist Financial increased their target price on shares of Integer from $137.00 to $145.00 and gave the stock a buy rating in a research note on Tuesday. Finally, Oppenheimer assumed coverage on shares of Integer in a research report on Tuesday, July 16th. They set an outperform rating and a $135.00 price target for the company. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Integer has a consensus rating of Moderate Buy and a consensus price target of $137.29.

Integer Price Performance

Shares of NYSE:ITGR opened at $127.19 on Tuesday. The firm has a market capitalization of $4.26 billion, a PE ratio of 44.01, a P/E/G ratio of 1.87 and a beta of 1.09. The company has a quick ratio of 1.96, a current ratio of 3.29 and a debt-to-equity ratio of 0.73. The company has a 50-day moving average price of $123.37 and a two-hundred day moving average price of $119.31. Integer has a twelve month low of $69.40 and a twelve month high of $131.87.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, July 25th. The medical equipment provider reported $1.30 earnings per share for the quarter, beating analysts’ consensus estimates of $1.24 by $0.06. The business had revenue of $436.20 million during the quarter, compared to analyst estimates of $437.00 million. Integer had a net margin of 6.31% and a return on equity of 11.48%. Integer’s revenue was up 9.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.14 EPS. Equities analysts forecast that Integer will post 5.31 EPS for the current year.

Insiders Place Their Bets

In other news, Director Jean M. Hobby sold 11,960 shares of the firm’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $119.66, for a total transaction of $1,431,133.60. Following the sale, the director now owns 2,280 shares in the company, valued at approximately $272,824.80. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 2.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ITGR. Quest Partners LLC boosted its holdings in shares of Integer by 3,688.9% in the 2nd quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 332 shares in the last quarter. GAMMA Investing LLC boosted its stake in Integer by 60.9% in the second quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 142 shares in the last quarter. Headlands Technologies LLC bought a new position in Integer during the first quarter valued at approximately $106,000. Innealta Capital LLC purchased a new position in shares of Integer during the second quarter worth approximately $110,000. Finally, Hancock Whitney Corp bought a new stake in shares of Integer in the 1st quarter worth approximately $203,000. Institutional investors own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.